THE COST SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BEVACIZUMAB-BASED THERAPY) TREATMENT COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CETUXIMAB-BASED THERAPY) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) ACROSS FOUR EUROPEAN COUNTRIES

被引：0
|
作者：
Nuijten, M. [1 ]
Chouaid, C. [2 ]
Vergnenegre, A. [3 ]
机构：
[1] Ars Accessus Med, Jisp, Netherlands
[2] Hop St Antoine, F-75571 Paris, France
[3] CHU Limoges, Limoges, France
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A41 / A41
页数：1
相关论文
共 50 条
  • [21] The cost-effectiveness of bevacizumab plus cisplatin and gemcitabine (BCG) compared with pemetrexed plus cisplatin (PC) induction treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in Germany.
    Bischoff, H.
    Hermes, A.
    Gatzemeier, U.
    Heigener, D. F.
    Cesaro-Tadic, S.
    Walzer, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations
    Hughes, DA
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (11) : 1655 - 1655
  • [23] Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer
    Schmid-Bindert, Gerald
    Gebbia, Vittorio
    Mayer, Frank
    Arriola, Edurne
    Marquez-Medina, Diego
    Syrigos, Kostas
    Biesma, Bonne
    Leschinger, Monika Iris
    Frimodt-Moller, Bente
    Ripoche, Veronique
    Myrand, Scott P.
    Nguyen, Tuan S.
    Hozak, Rebecca R.
    Zimmermann, Annamaria
    Visseren-Grul, Carla
    Schuette, Wolfgang
    LUNG CANCER, 2013, 81 (03) : 428 - 434
  • [24] Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG)
    Kotsakis, A.
    Kentepozidis, N.
    Emmanouilidis, Ch.
    Polyzos, A.
    Agelidou, A.
    Vaslamatzis, M.
    Chandrinos, V.
    Agelaki, S.
    Vamvakas, L.
    Kalbakis, K.
    Katsaounis, P.
    Stoltidis, D.
    Nintos, G.
    Hatzidaki, D.
    Vetsika, E. K.
    Mavroudis, D.
    Georgoulias, V.
    LUNG CANCER, 2015, 88 (01) : 57 - 62
  • [25] Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan
    Ahn, Myung-Ju
    Tsai, Chun-Ming
    Hsia, Te-Chun
    Wright, Elaine
    Chang, John Wen-Cheng
    Kim, Heung Tae
    Kim, Joo-Hang
    Kang, Jin Hyoung
    Kim, Sang-We
    Bae, Eun-Jin
    Kang, Mijeong
    Lister, Johanna
    Walzer, Stefan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 : 22 - 33
  • [26] Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
    Rosell, R.
    Robinet, G.
    Szczesna, A.
    Ramlau, R.
    Constenla, M.
    Mennecier, B. C.
    Pfeifer, W.
    O'Byrne, K. J.
    Welte, T.
    Kolb, R.
    Pirker, R.
    Chemaissani, A.
    Perol, M.
    Ranson, M. R.
    Ellis, P. A.
    Pilz, K.
    Reck, M.
    ANNALS OF ONCOLOGY, 2008, 19 (02) : 362 - 369
  • [27] A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Barata, F.
    Parente, B.
    Teixeira, E.
    Costa, A.
    Fernandes, A.
    Pimentel, F. L.
    Carvalho, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naive patients
    Leon, Luis
    Vazquez, Sergio
    Manuel Gracia, Jose
    Casal, Joaquin
    Lazaro, Martin
    Luis Firvida, Jose
    Amenedo, Margarita
    Santome, Lucia
    Macia, Sonia
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (10) : 1389 - 1396
  • [29] An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia
    Chang, John Wen-Cheng
    Thongprasert, Sumitra
    Wright, Elaine
    Tsang, Kenneth
    Kim, Heung Tae
    Ahn, Myung-Ju
    Kim, Joo-Hang
    Kang, Jin Hyoung
    Kim, Sang-We
    Walzer, Stefan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 : 13 - 21
  • [30] Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX).
    Von Pawel, J.
    Park, K.
    Pereira, J. R.
    Szczesna, A.
    Yu, C.
    Ganul, V. L.
    Krzakowski, M.
    Roh, J. K.
    Pilz, K.
    Pirker, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 391S - 391S
12345